Accelerated filament formation from tau protein with specific FTDP-17 missense mutations  by Nacharaju, Parimala et al.
Accelerated ¢lament formation from tau protein with speci¢c FTDP-17
missense mutations
Parimala Nacharaju, Jada Lewis, Colin Easson, Samuel Yen, Jennifer Hackett, Mike Hutton,
Shu-Hui Yen*
Departments of Pharmacology and Biochemistry and Molecular Biology, Mayo Clinic Jacksonville, 4500 San Pablo Road,
Jacksonville, FL 32224, USA
Received 28 January 1999
Abstract Tau is the major component of the neurofibrillar
tangles that are a pathological hallmark of Alzheimers’ disease.
The identification of missense and splicing mutations in tau
associated with the inherited frontotemporal dementia and
Parkinsonism linked to chromosome 17 demonstrated that tau
dysfunction can cause neurodegeneration. However, the mechan-
ism by which tau dysfunction leads to neurodegeneration remains
uncertain. Here, we present evidence that frontotemporal
dementia and Parkinsonism linked to chromosome 17 missense
mutations, P301L, V337M and R406W, cause an accelerated
aggregation of tau into filaments. These results suggest one
mechanism by which these mutations can cause neurodegenera-
tion and frontotemporal dementia and Parkinsonism linked to
chromosome 17.
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1. Introduction
Frontotemporal dementia and Parkinsonism linked to chro-
mosome 17 (FTDP-17) is a neurological disorder character-
ized by early personality changes as well as deterioration of
memory and language [1^6]. In this disease, hyperphosphoryl-
ated tau inclusions are observed in neurons and variably in
glia in a¡ected cortical and subcortical regions [3,7^9].
The tau isoform composition and ¢lament morphology in
these inclusions varies in di¡erent forms of FTDP-17. The
explanation for this variability was recently determined with
the identi¢cation of missense and 5P splice-site mutations of
exon 10 in the tau gene [10^12]. There is a clear correlation
between the type of tau mutation and the biochemical and
ultrastructural ¢ndings in FTDP-17. Mutations that a¡ect
exon 10, either missense (P301L and N279K) or 5P splice-
site mutations (+3, +13, +14 and +16), are associated with
inclusions that contain predominantly tau isoforms with four
microtubule-binding repeats [8,13] and ¢laments with a longer
periodicity (twisted ribbons) [7,8] than the paired helical ¢la-
ments (PHFs) observed in Alzheimer’s disease (AD) [14,15].
In addition, these mutations are associated with the presence
of glial tau pathology [7,8]. In contrast, missense mutations
outside exon 10 (G272V, V337M and R406W) are associated
with inclusions largely restricted to neurons [3,5] that contain
all six tau isoforms [13,16,17] as in AD [18] and the ¢laments
morphologically resemble PHF [5,16,17].
Tau is capable of forming ¢laments in vitro, especially when
incubated with polyanions such as heparin [19^21], RNA [22]
or arachidonic acid [23]. The morphology of in vitro polymers
depends on the tau isoform used, 3-repeat tau generates PHF-
like ¢laments while 4-repeat isoforms generate straight ¢la-
ments [19]. The microtubule-binding domain is essential for
the formation of tau ¢laments in vitro [19,20,24]. Since the
missense mutations in FTDP-17 are within or adjacent to the
microtubule-binding domain, these might be expected to in-
£uence the ability of tau to form ¢laments. We therefore
compared the polymerization potential of recombinant wild-
type and mutant tau in the presence and absence of polymer-
ization-inducing agents.
2. Materials and methods
2.1. Generation of constructs and mutagenesis
A NdeI-EcoRI human tau cDNA fragment (exons 1^5, 7, 9^13) in
pUC19 was mutagenized with the Gene Editor site-directed mutagen-
esis kit (Promega) and the selection primer (5P-CCGCGAGACC-
CACCCTTGGAGGCTCCAGATTTATC-3P). The sequences of
mutagenesis oligos were: P301L 5P-AACACGTCCTGGGAGGCG-
3P, R406W 5P-GGGACACGTCTCCATGGCATCTCAGCAAT-3P,
V337M 5P-CAGGAG GTGGCCAGATGGAAGTAAAATCTG-3P.
Mutagenesis was performed according to the manufacturer’s instruc-
tions. DNA was isolated from mutant and wild-type clones and the
tau cDNA sub-cloned in frame into the expression vector pRK172.
Tau cDNA constructs were sequenced using the BigDye Terminator
Cycle Sequencing Kit (Perkin Elmer). Sequencing was performed on
an ABI377 automated sequencer with Sequence Navigator software
(Perkin Elmer).
2.2. Expression and puri¢cation of recombinant tau
Recombinant wild-type and mutant tau (longest isoform, 441 resi-
dues) was expressed in Escherichia coli as described previously [25].
Protein was extracted from the bacterial pellet with 20 mM 4-morpho-
line ethane sulfonic acid (MES), 0.8 M NaCl, 1 mM MgCl2, 1 mM
EDTA, 0.2 mM phenylmethylsulfonyl £uoride (PMSF), pH 6.8. The
extract was dialyzed against the same bu¡er without salt. Ammonium
sulfate was added to 50% saturation and the precipitated proteins
were collected by centrifugation at 40 000Ug. The pellet was resus-
pended in 50 mM MES, 5 mM dithiothreitol (DTT), pH 6.25 and
dialyzed overnight against the same bu¡er. The sample was chromato-
graphed on CM Sepharose, using a salt gradient of 0^0.5 M NaCl
[26]. Fractions containing tau were pooled, dialyzed against water and
lyophilized. The purity of the tau was determined by SDS-PAGE and
Western blotting.
2.3. Polymerization of tau
Wild-type and mutant tau (0.1 mg/ml) was incubated with or with-
out heparin (0.01 mg/ml) in 30 mM MOPS, 2 mM PMSF, pH 7.4, at
37‡C. For arachidonic acid-induced polymerization, tau was incu-
bated at a concentration of 0.2 mg/ml with or without 80 WM arach-
idonic acid in 50 mM borate bu¡er, 10 mM DTT, 80 mM NaCl, 1 mM
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MgCl2, 2 mM PMSF, 1 mM EDTA, 2 mM EGTA, pH 8.0, at 37‡C.
Aliquots were removed at indicated time intervals and placed on 200-
mesh copper grids coated with formvar and carbon for 2 min [23].
The grids were drained and stained with 2% uranyl acetate for 2 min.
Finally, the grid was rinsed with water and dried. The ¢laments on the
grids were monitored using a Philips EM208S electron microscope.
After examining the whole grid at 4400U magni¢cation, at least ¢ve
representative ¢elds for each grid were recorded using the Digital
Micrograph software (Gatan). The total ¢lament length was deter-
mined for each ¢eld using SigmaScan Pro (Jandel Scienti¢c) to give
an indication of the relative ¢lament mass. Tau ¢laments measuring at
least 100 nm were included in the data [23]. The average ¢lament
length per ¢eld was calculated. The average value from duplicate
experiments was plotted.
3. Results
3.1. Heparin-induced polymerization of wild-type and mutant
recombinant tau
The longest tau isoform (441 residues) and mutants, P301L,
V337M and R406W, were polymerized at 0.1 mg/ml in the
presence of heparin (0.01 mg/ml). All tau species formed ¢la-
ments but the kinetics was di¡erent in each case (Fig. 1). After
incubation for 1 day, the P301L mutant generated a V7-fold
higher mass of ¢laments than either wild-type tau or the other
mutants (Fig. 2). V337M gave no signi¢cant di¡erences in
polymerization compared to wild-type tau after 1 day, but
displayed a 2-fold increase after 2 days incubation. The
R406W mutant generated a smaller mass of ¢laments than
wild-type tau after 2^3 days of incubation, but thereafter dis-
played a dramatic acceleration in ¢lament formation (Fig. 1).
The most rapid phase of net growth of ¢lament mass was on
days 0^1 for P301L, days 1^2 for V337M, days 2^3 for wild-
type and days 3^4 for R406W. The total mass of ¢laments
formed after 4 days was in the order R406WsP301Lswild-
type = V337M (2.5:1.8:1.1:1, respectively) (Fig. 1). Polymer-
ization of P301L and R406W tau remained active in samples
with 4 days of incubation. However, the growth of ¢laments
in V337M samples reached a plateau on day two and in wild-
type sample on day three. The di¡erences in the kinetics of tau
polymerization were reproducible in duplicate experiments.
Polymers generated by wild-type and mutant tau with hep-
arin were similar in ultrastructure (data not shown). They
appeared as straight ¢laments with a diameter of V20 nm
[19]. The ¢lament length increased as the incubation time
was extended. When placed on grids, the ¢laments usually
distributed evenly. Only in samples containing numerous ¢la-
ments, as in mutants P301L and R406W after 4 days incuba-
tion, were ¢lament clusters observed (Fig. 2). The ¢laments in
these clusters, however, did not form bundles.
3.2. Arachidonic acid-induced polymerization of wild-type and
mutant recombinant tau
Wild-type and mutant tau (0.2 mg/ml) was also polymerized
in the presence of arachidonic acid (80 WM). Under these
conditions, P301L tau again formed ¢laments most rapidly
(Fig. 3). After a 2 day incubation, the mass of ¢laments gen-
erated had the following order: P301LsV337Mswild-
typesR406W. These results are similar to those obtained
with heparin after this incubation period (2 day). After a
4 day incubation, a qualitative assessment indicated that the
R406W mutant had formed more polymers than wild-type
tau but less than the P301L or V337M mutants (data not
shown). This result is consistent with the time course observed
with the R406W mutant incubated with heparin, where the
mutant exhibited a dramatic but delayed acceleration in poly-
merization compared to wild-type tau. The morphology of
¢laments generated with arachidonic acid and heparin was
almost indistinguishable. However, arachidonic acid-induced
tau polymers often formed bundles (Fig. 3) which prevented a
detailed quantitative assessment.
3.3. Polymerization of wild-type and mutant tau in the absence
of inducing agents
In the absence of polymerization-inducing agents, no ¢la-
ments were detected with wild-type or mutant tau after 4 days
incubation. However, with a prolonged incubation (9 days),
an appreciable number of short ¢laments were observed with
the P301L mutant (Fig. 4) but not with wild-type or the other
tau mutants. In addition, P301L tau uniquely formed a large
number of spherical structures interpreted as proto¢laments
(Fig. 4). These results are consistent with the observation that
the initial rate of polymerization is fastest with P301L in the
presence of either heparin or arachidonic acid.
4. Discussion
Our results demonstrate that the FTDP-17 missense muta-
tions tested have a pronounced e¡ect on tau self-interaction.
Each mutation has a unique e¡ect on the kinetics of in vitro
tau polymerization. The P301L mutant displayed the highest
initial rate of polymerization under all conditions tested. Most
patients with P301L mutations develop disease at a relatively
early age (40^50 years), compared with other FTDP-17 cases
with missense mutations, and display a massive fronto-tempo-
ral cell loss [6,10]. Interestingly, soluble tau isolated from the
brains of patients with this mutation has been reported to
have unusually low levels of 4-repeat isoforms presumably
because the mutant P301L tau is readily incorporated into
insoluble tau ¢laments [13]. This observation is entirely con-
sistent with the results presented here.
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Fig. 1. Kinetics of polymerization of wild-type and mutant tau. Tau
(0.1 mg/ml) was incubated with heparin (0.01 mg/ml) at pH 7.4 and
37‡C. Aliquots removed at the indicated time intervals were stained
with 2% uranyl acetate on copper grids. The digital electron micro-
graphs of 5^10 representative low magni¢cation ¢elds of each grid
were recorded. The ¢lament length was measured and the average
length per ¢eld was calculated. The average of the values from du-
plicate experiments was plotted. The T bar represents the di¡erence
between the individual value and the corresponding average.
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Fig. 2. Tau ¢laments formed in the presence of heparin. Tau proteins were polymerized as described for Fig. 1. The representative ¢elds from
wild-type (A, E) and corresponding mutants P301L (B, F), V337M (C, G) and R406W (D, H) after 1 day (A^D) and 4 days incubation (E^H)
were shown. Scale bar = 0.75 Wm.
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The greater potential of P301L tau for self-interaction may
be due to the location of this mutation in a conserved PGGG
motif in the microtubule-binding domain. This motif is
present in all the four microtubule-binding repeats. Previous
studies have shown that in vitro tau ¢lament formation is
dependent on the microtubule-binding domain [19,20,24].
Thus, the conformational change generated by replacement
of leucine for proline in one of these domains may destabilize
tau-tubulin interactions and favor tau-tau self-interaction. Ac-
cordingly, the P301L mutation has also been reported to
cause the most dramatic reduction (of the mutations tested)
in tau-induced in vitro tubulin polymerization [27].
The V337M mutation is located in the variable region of
the fourth microtubule-binding repeat. The V337M mutant
also exhibited a higher rate of tau ¢lament polymerization
than wild-type, but only in the initial stages of polymerization.
It remains unclear why polymerization of V337M mutant tau
reaches a plateau sooner than that of other recombinant tau
proteins. However, it seems likely that the V337M mutation
accelerates the nucleation of ¢laments but has little e¡ect on
the subsequent phases of tau polymerization.
Initial polymerization of the R406W mutant was slower
than other types of tau but after a delay, the rate increased
rapidly in the presence of either heparin or arachidonic acid.
Indeed, the mass of ¢laments formed in the presence of hep-
arin was greater than with other recombinant tau proteins
after 4 days incubation. The R406W mutation thus seems to
be inhibitory to nucleation. The reason for this could be due
to the loss of a positively charged residue from the C-terminal
region of tau, the region that contains one of the heparin
binding sites of tau [19]. This may a¡ect the interaction be-
tween tau and the anionic polymerization inducer [19^22]
which may in turn result in a reduced rate of nucleation.
The slow initial rate of R406W tau ¢lament formation is
interesting in the light of the clinical phenotype in the
FTD004 family that carries this mutation [5]. Patients from
this family develop disease with a relatively late age of onset
(55 years) and the disease duration is longer than observed in
most other FTDP-17 families [5]. Thus, the slower initial ki-
netics of R406W tau ¢lament formation may be re£ected in
the clinical phenotype of this family. It must be acknowl-
edged, however, that correlations drawn between these in vi-
tro assays and the clinical features in di¡erent FTDP-17 fam-
ilies must be treated with caution since numerous genetic and
environmental factors presumably in£uence the pathogenesis
of this disease.
Analysis of the biophysical properties of wild-type, P301L,
V337M, R406W and G272V recombinant tau using HPLC
elution and circular dichroic spectra has revealed that each
mutation causes a similar alteration in tau con¢rmation (Peter
Davies, MH, unpublished results). Each missense mutation
results in an increase in the apparent K-helical content of
the tau molecule. The result of this conformational change
seems to shift the structure of tau away from that which
favors microtubule-binding/polymerization to a structure
that favors self-interaction.
The results presented here on tau polymerization and pre-
vious observations that tau missense mutations reduce micro-
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Fig. 3. Representative ¢elds of tau ¢laments formed in the presence of arachidonic acid. Wild-type tau (A) and its mutants P301L (B), V337M
(C) and R406W (D) were incubated at a concentration of 0.2 mg/ml with arachidonic acid (80 WM) at pH 8.0 and 37‡C for 2 days. Note that
the ¢laments were bundled. Scale bar = 0.75 Wm.
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tubule-binding and polymerization [13,27] are consistent with
a dual e¡ect of the FTDP-17 mutations. However, further
studies will be needed to investigate which of these two mech-
anisms, or both, are critical to the pathogenesis of FTDP-17.
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Fig. 4. Polymerization of the P301L mutant without polymerization
inducing agents. Wild-type tau (A) and mutant P301L (B) were in-
cubated at a concentration of 0.2 mg/ml in 50 mM borate bu¡er,
10 mM DTT, pH 8.0 at 37‡C for 9 days. Note the short ¢laments
and spherical structures formed with P301L (B). Scale bar = 0.38 Wm
(for A) and 0.18 Wm (for B).
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